Articles on Cancer
THE USE OF A WHEY PROTEIN CONCENTRATE IN THE TREATMENT OF PATIENTS WITH METASTATIC CARCINOMA: A PHASE I-II CLINICAL STUDYRenee S. Kennedy, George P. Konok, Gustavo Bounous, Sylvain Baruchel, Timothy D. G. Lee
Abstract: This preliminary study indicates that this newly discovered property of whey proteins may be a promising adjunct in the nutritional management of cancer patients about to undergo chemotherapy. Selective depletion of tumor GSH may in fact render the malignant cells more vulnerable to the action of chemotherapeutic agents. ->>Read more.<<-
WHEY PROTEINS IN CANCER PREVENTIONG. Bounous, G. Batist, P. Gold (The Montreal General Hospital and McGill University, Montreal, Quebec, Canada)
Abstract: Epidemiological and experimental studies suggest the dietary milk products may exert an inhibitory effect on the development of several types of tumors. Some recent experiments in rodents indicate that the antitumor activity of the dairy products is in the protein fraction and more specifically in the whey protein component of milk. We and others have demonstrated that whey protein diets result in increased glutathione (GSH) concentration in a number of tissues, and that some of the beneficial effects of whey protein intake are abrogated by inhibition of GSH synthesis. When protein is particularly rich in substrates for GSH synthesis. We suggest that whey protein may be exerting its effect on carcinogenes by enhancing GSH concentration. ->>Read more.<<-
DIETARY WHEY PROTEIN INHIBITS THE DEVELOPMENT OF DIMETHYLHYDRAZINE INDUCED MALIGNANCYGustavo Bounous, Robert Patenburg, Patricia A. L. Kongshavn, Phil Gold, and David Fleiszer (Departments of Physiology and Medicine, Montreal General Hospital and McGill University)
Abstract: This study investigates the influence of two formula diets containing 20g / 100g diet of either whey protein concentrate or casein or Purina mouse chow, on the humoral immune responsiveness and dimethylhydrazine induced colon carcinogenes in A / J mice. After 20 weeks of dimethylhydrazine treatment, the number of plaque forming cells per spleen, following intravenous inoculation with 5 X 106 sheep red blood cells, was nearly three times greater in the whey protein-fed group than in the casein-fed mice although both values were substantially below normal. After 24 weeks of dimethylhydrazine treatment the incidence of tumors in the whey protein-fed mice was substantially lower than that in mice fed either the casein or Purina diet. Similarly, the tumor area was less in the whey protein group in comparison to either the casein or Purina groups, with some difference between casein and Purina groups. Body weight curves were similar in all dietary groups.
In conclusion, a whey protein diet appears to significantly inhibit the incidence and growth of chemically induced colon tumors in mice. ->>Read more.<<-
WHEY PROTEIN CONCENTRATE (WPC) AND GLUTATHIONE MODULATION IN CANCER TREATMENTGustavo Bounous
Abstract: The glutathione (GSH) antioxidant system is foremost among the cellular protective mechanisms. Depletion of this small molecule is a common consequence of increased formation of reactive oxygen species during increased cellular activities. This phenomenon can occur in the lymphocytes during the development of the immune response and in the muscular cells during strenuous exercise. (Open file for further anticancer info in the abstract) Case reports are presented which strongly suggest an anti-tumor effect of a whey protein dietary supplement in some urogenital cancers. This non toxic dietary intervention, which is not based on the principles of current cancer chemotherapy, will hopefully attract the attention of laboratory and clinical oncologists.
CASE REPORTS (found within file)
Showing the Effect of Whey Protein Concentrate (WPC)1 on Urogenital Malignancies
Treatment of Uterine Carcinoma in Situ:
Daniel Moreau, MD
Ottawa Civic Hospital, Canada
Whey Proteins in the Treatment of Metastasis of Renal Carcinoma
Robert Bender, MD, medical director
Community Medical Group of Corona, Corona, CA, U.S.A.
A Prospective Study of the Effect of Speciall Prepared Whey Protein Concentrate on the Progression of Cancer of the Prostate
John M. Zaborowski, MD
Physicians Care Center, Chicago, IL, U.S.A.
Whey Protein in the Treatment of Metastatic Prostate Cancer
Roger G. Mazlen, MD
Mount Sinai Medical School and Medical Center, New York, U.S.A.
Whey Protein in the Treatment of Bladder Cancer
A Prospective Study of the Effect of Specially Prepared whey Protein Concentrate on the Progression of Cancer of the Prostate
Bela S. Benes, MD director
The Prostate Center of Greater St-Louis, Missouri, U.S.A.
Improvement in PSA Values Using Oral Glutathione Precursors Obtained from Specially-Prepared Whey Protein Concentrate (SWPC)
Jimmy Gutman, MD
Department of Family Medicine, Emergency Medicine, McGill University, Canada April 2000
Acknowledgements: The work performed by Dr. Gustavo Bounous was supported by the Medical Research Council of Canada of which he was a career investigator from 1968 to 1993, the year of his retirement from McGill University. The invaluable contribution of John H. Molson is gratefully acknowledged.
ENHANCING EFFECT OF PATENTED WHEY PROTEIN ISOLATE (IMMUNOCAL®) ON CYTOTOXICITY OF AN ANTICANCER DRUGWayne Y. Tsai, Wen-Huei Chang, Ching-Hsein Chen, and Fung-Jou Lu (Department of Biochemistry, College of Medicine National Taiwan University, Taipei, Taiwan, ROC.)
Abstract: To determine the enhancing effect of a whey protein isolate on the cytotoxicity of a potential anticancer drug, baicalein, the human hepatoma cell line Hep G2 was assigned to grow in different media for four days, and cell growth and apoptosis were investigated. The control group was grown in normal medium; the other three groups were grown in whey protein isolate (Immunocal) medium, baicalein medium, and a combination of Immunocal and baicalein. As indicated by 3-(4,5-dimethylthiazol-2-yl)-2,3-diphenyl tetrazolium bromide assay, survival rate was significantly lower in cells grown in baicalein + Immunocal than in cells grown in baicalein alone. In contrast, there was no significant difference in the survival rate of the cells grown in Immunocal. In the investigation of apoptosis, cells grown in baicalein + Immunocal showed a higher phosphatidylserine exposure, lower mitochondiral transmembrane potential, and nearly 13 times more cells undergoing apoptosis than cells grown in baicalein alone. We also demonstrated that Immunocal reduced glutathione (GSH) in Hep G2 cells by 20-40% and regulated the elevation of GSH, which was in response to baicalein. In conclusion, Immunocal seemed to enhance the cytotoxicity of baicalein by inducing more apoptosis; this increase in apoptotic cells may be associated with the depletion of GSH in Hep G2 cells. This is the first study to demonstrate, in vitro, that Immunocal may function as an adjuvant in cancer treatments. ->>Read more<<-